Background: This study was designed to explore the effectiveness and tolerability of a weekly regimen of epirubicin and vinorelbine plus granulocyte colony-stimulating factor (G-CSF).
Introduction
Metastatic breast cancer is currently incurable, so palliation and the possibility of prolonged survival are the only achievable aims. As a result, chemotherapy has changed little since the 1980s. The most commonly used first-line regimens use anthracyclines such as fluorouracil, adriamycin and cyclophosphamide (FAC) or fluorouracil, epirubicin and cyclophosphamide (FEC), affording response rates of 40%-60% [1, 2] , and median survivals between 18 and 24 months. Epirubicin, an adriamycin analog with reduced cardiac toxicity, usually yields objective responses in 30%-40% of cases [3] [4] [5] as a single agent.
Weekly drug schedules have been proposed in the hope of reducing hematological and cardiac toxicity and thereby rendering treatment acceptable for patients in poor general condition. Anthracyclines administered in this way show the same degree of activity with less severe toxicity [6] [7] [8] . The advent of new drugs like vinorelbine and the taxanes in the 1990s affords therapeutic alternatives, and such agents can be used as single drugs and in association with anthracyclines. Vinorelbine is a semi-synthetic vinca alkaloid differing chemically from vinblastine by a modification of the catharanthine moiety of the molecule [9] . It acts by inhibiting the polymerization of cell microtubules, thereby disrupting mitotic spindle formation and arresting cell growth in the metaphase. Used as a single agent, vinorelbine (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) mg/m 2 on days 1 and 8 every three weeks) has proved to be very active in advanced breast cancer as first-line therapy (response rates between 41% and 60% [10] [11] [12] [13] [14] and as second-line therapy (30%-42%) [14] [15] [16] [17] [18] [19] . The dose-limiting toxicity of vinorelbine is hematological and, to a lesser extent, neurological.
In an earlier study, we showed that the dose intensity of vinorelbine could be increased by giving the drug without interruption in weekly doses of 25 mg/m 2 and concurrently using the granulocyte colony-stimulating factor (G-CSF) [20] . With such a schedule, a 47% objective response rate was obtained in 40 heavily pretreated patients, with a median response duration of 11 months and median time to progression of 8.3 months. Despite the increased dose intensity achieved, vinorelbine toxicity never exceeded grade 2 and neurological toxicity assessed clinically and electromyographically was likewise mild and completely reversible [21] . Recently, Livingston et al. [22] showed that it is possible to obtain an increased dose-intensity of 27.7 mg/m 2 /week, with growth factors, in previously treated patients with advanced breast cancer.
In patients with previously untreated advanced breast cancer, the combination of doxorubicin and vinorelbine has provided a 74% response rate with a 12-month response duration and 27.5-month median survival [23] . The schedule administered the anthracycline on day 1 and vinorelbine on days 1 and 8, repeated every three weeks with a dose intensity of 12.5 mg/m 2 /week for doxorubicin and 14 mg/m 2 /week for vinorelbine. The rationale for the proposed schedule is based on the previous experience with both single agents [20, 24] , the results reported by Spielmann et al. [23] with the combination of adriamycin and vinorelbine, and the possibility of exploring the dose-density theory [25] . We thus designed the multicenter phase II study to explore the effectiveness and tolerability of an intensive epirubicin and vinorelbine plus G-CSF regimen given weekly to chemotherapy-naive patients with metastatic disease. S= grade 2), the growth factor was given in doses of 150 |ig/m on days 2, 3 and 4 after onset. In the remaining 17 cases (group B), G-CSF was included in the treatment schedule on days 2 and 4 without a wait for neutropenia to develop. The lack of febrile neutropenia in group A led us to reduce G-CSF usage; the schedule of G-CSF every other day was used on the basis of the duration of its effect on bone marrow (36-48-hour) . The weekly regimen of epirubicin + vinorelbine was administered for 24 weeks in the absence of progression; after that, no hormone therapy was given for maintenance.
Emesis was prevented with 8 mg of ondansetron given intravenously before chemotherapy plus 12 mg of dexamethasone, again intravenously, after the vinorelbine infusion.
Toxicity and dose modifications
Toxicity was assessed by WHO criteria. Asthenia and myalgia (treatment and G-CSF related) were graded as absent, mild, moderate, or severe. No dose reductions were made for toxicity. For hematological toxicity of grade 2 or more, treatment was interrupted until WBC was restored to 2500/mm 3 and the neutrophil count was better than 1500 mm 3 . With non-hematological toxicity in excess of grade 2, treatment was suspended until recovery to WHO grade 0 criteria. For WHO 3= grade 2 cardiac toxicity, treatment was withdrawn.
Patients and methods

Patient selection
Eligible patients were those with histologically-documented breast cancer, measurable or assessable metastatic lesions, life expectancy > 3 months, age under 75 years, and ECOG performance status < 3. Measurable lesions could not occupy previously irradiated fields. Assessable but not measurable lesions included pleural effusion, ascites and lytic bone metastases. Other requirements were adequate bone marrow function (hemoglobin 5= 9 g/dl, WBC count > 3500 mm 3 with neutrophils ^2000 mm 3 and platelet count 2*100,000 mm 3 ); acceptable liver and renal function (bilirubin and transaminase assays not worse than 1.5 times the upper limit of normal, blood creatinine < 2 mg/dl); and adequate cardiac function, no active cardiac disease, and left ventricular ejection fraction > 50%. All patients gave their informed consent. Patients with a record of previous chemotherapy for metastatic disease or an adjuvant anthracycline-based treatment during the previous two years (prior maximum cumulative dose of an anthracycline 480 mg/m 2 for epirubicin and 300 mg/m 2 for doxorubicin) were excluded. Also excluded were those with brain metastases, inadequate bone marrow reserve, and renal or cardiac insufficiency.
Response criteria
WHO criteria were used to evaluate responses [26] . Criteria used to define a complete response of bone metastases were the disappearance of all osteolytic lesions, normalized bone scan for at least four weeks, and no need for pain medication. A partial response was defined as improvement or stability of X-ray pictures with reduced intensity and number of high-uptake areas in scintiscans, alleviation of bone pain allowing at least 50% reduction of analgesic dosages, and an improvement in performance status by at least one grade for at least four weeks.
Overall responses were assessed at 12 and 24 weeks of treatment by repeating the same investigations performed before starting it. Response duration was defined as the interval between the start of treatment and progression time, and survival was calculated from the first day of treatment.
The dose intensity (mg/m 2 /week) was calculated for the two drugs as described by Hryniuk [27] and survival curves according to . Differences between the curves were assessed by the log-rank test and those between response rates by the chi-square test.
Results
Pretreatment assessment and follow-up
At entry to the study, each patient was given a complete physical examination, a battery of laboratory tests including CEA and CA 15-3, and underwent radiological studies (conventional X-ray films, ultrasounds, and bone scans, plus CT scans when needed). Pretreatment cardiac evaluation included ECG tracings and left ventricular ejection fraction measurements with echocardiogram. Blood count and platelet tests were repeated weekly on the day of treatment; complete biochemical screening plus ECG were done every four weeks; recheck echocardiograms were obtained at 24 weeks of treatment.
Treatment regimen
Epirubicin was administered once a week as a bolus of 25 mg/m 2 i.v.; vinorelbine as a 20 min i.v. infusion of 25 mg/m 2 in 100 ml of normal saline. To insure a high-dose intensity. G-CSF was given concurrently. In the first 35 cases (group A: patients showing neutropenia of WHO Between April 1994 and July 1996, 52 patients with advanced breast cancer were entered; all were assessable for response and toxicity. Patient characteristics are given in Table 1 . All patients received at least four courses of treatment (median 22; range 10-24).
Response to treatment and dose intensity
Forty of fifty-two patients showed a response, for an objective response rate of 77% (95% CI: 66%-88%), with 10 complete (19%) and 30 partial responses (58%). Disease stabilization was achieved in 12 patients (23%); no progression was observed during treatment ( 
19-24 weeks
• Group A Q Group B for epirubicin and vinorelbine, representing 92% of the theoretical dose.
Toxicity
All patients were assessable for toxicity in a total of 1065 weekly courses. Treatment was delayed because of hematological toxicity in connection with 70 courses (6.5%): for chemical phlebitis in one case, severe asthenia in 3 cases, and unrelated causes in 11. The median treatment delay was one week, and it never exceeded two weeks. Neutropenia of grades 3 and 4 was the most frequent toxicity. It occurred in 39% of patients and lasted less then seven days; however, there were no episodes of febrile neutropenia or neutropenic sepsis. Grades 3 and 4 neutropenia developed in 15 of 35 patients of group A (43%) within the first six weeks of treatment. Despite G-CSF treatment, 6% of patients continued to suffer episodes of grade 3-4 neutropenia of a median duration of one week (range 1-2). In group B, 2 of 17 patients (12%) had grade 3-4 neutropenia in the first 6 weeks of treatment, which never lasted longer than 7 days (Figure 1 ). Groups A and B differed statistically in number of patients with neutropenia and number of courses in which neutropenia was present, especially in the first six weeks (P < 0.0001).
Only one patient in the entire series (2%) developed grade 3 anemia, and only two (4%) developed grade 3 cardiotoxicity, one in the form of acute myocardial infarction and one of cardiac failure; both recovered without sequelae. Both of these patients were hypertensive and one had received epirubicin (480 mg/m 2 ) during adjuvant chemotherapy. Treatment was discontinued after 16 courses in one case (400 mg/m 2 epirubicin) and after 15 courses (375 mg/m 2 epirubicin) in the other. Peripheral neurological toxicity was reversible and never severe enough to interfere with the continuation of treatment. No cases of grades 3 and 4 mucositis were reported. Gastrointestinal tolerability was excellent. Grade 2 alopecia was seen in 21 patients (40%) and grade 3 in 14 (27%). Moderate to severe asthenia occurred in 38% of the patients and 5% of the cycles. Toxicity data are shown in Table 3 . Mild and moderate myalgia related to G-CSF administration occurred in most of the patients but did not interfer with the therapy.
Survival
The median survival was 31 months, with a median follow-up of 24 months (range 9-40). Sixty-one percent of the patients are alive at 24 months (Figure 2) . No significant differences emerged with regard to prognostic factors such as menopausal status, hormone receptors, disease-free survival, number of metastatic sites, dominant metastatic site, or prior chemotherapy and responses. A statistically significant difference (P < 0.04) was seen only for performance status (PS 0 vs. PS 1 vs.
PS 2).
Discussion
This weekly schedule of epirubicin and vinorelbine plus G-CSF proved to be remarkably effective in advanced breast cancer, yielding an objective response rate of 77% in a series of 52 consecutive cases, with all responses confirmed after three months. Patients with visceral lesions as the dominant metastatic site responded particularly well, with an 83% objective response rate. Considered together with the absence of disease progression during treatment in the series as a whole, the results underscore the effectiveness of the treatment. The median response duration and time to progression were both 10 months. Toxicity was low: there were no cases of febrile neutropenia, sepsis, or hospitalization in 39% of the patients who developed grade 3-4 neutropenia of short duration. The most common nonhematological toxicity was asthenia; cardiac toxicity occurred in only two patients; neurological and gastrointestinal toxicity were negligible.
Compared with the results obtained with either of the drugs alone [4, 5, 15, 16] , our results showed a 30% increase in response rates. Response duration and time to progression did not significantly differ from previously published data [1, 2] . Spielmann et al. [23] were the first investigators to use vinorelbine plus anthracyclines in combination in the treatment of advanced breast cancer, and they achieved impressive results. The response rate in their study was 74%, with a response duration of 12 months and a median survival of 27.5 months, which represents a significant achievement for the patient population. The main toxicities observed in their trial were hematological and cardiac: 56% of patients had fever and 16% had febrile neutropenia. There were four cases of shock due to neutropenic sepsis (two of which proved fatal) and three deaths from cardiac toxicity.
In the present study, by substituting epirubicin for adriamycin [29] and keeping to the same cumulative administered dose, we confirmed the activity of the combination. The weekly schedule allowed us to obtain an improvement in dose intensification of 30% and 40% for epirubicin and vinorelbine, respectively. The increase in doses did not result in increased toxicity, because with growth factor support, hematological toxicity was diminished and produced very few serious clinical consequences. Although it was not our intention to define the optimal schedule for G-CSF therapy, we noted that early treatment with the growth factor not only reduced the incidence and severity of neutropenia during the first six weeks but also prevented the occurrence of grade 2 or worse neutropenia in the remainder of the treatment time (30% among patients of group A, 6% in those of group B).
The effectiveness of the anthracycline/vinorelbine combination has been confirmed from other quarters. In a dose-finding study of 40 patients receiving epirubicin instead of adriamycin, Blomqvist et al. [30] determined a maximum tolerable dose of 60 mg/m 2 every three weeks for epirubicin and 20 mg/m 2 for vinorelbine on days 1 and 8, with a response rate of 60% but at the price of grade 3-4 neutropenia in 75% of the patients and two severe cases of febrile neutropenia (one fatal). A similar study conducted by Chadjaa et al. [31] on 30 patients yielded a 60% objective response rate but produced grade 3-4 granulocytopenia in 36 of 174 cycles (21%), including 1 case ofgranulocytopenic fever. Weekly dosing with anthracyclines seems a preferable alternative to the classical three-week schedule, with comparable therapeutic activity and less toxicity.
Weekly dosing is encouraged by pharmacokinetic considerations. In a comparative study of adriamycin at 75 mg/m 2 i.v. every three weeks versus the same drug at 25 mg/m 2 once a week, Twelves et al. [32] showed that peak plasma levels were the same but total exposure to adriamycin was greater with the weekly schedule because of the difference in clearance, and this makes the weekly modality almost equivalent to a continuous infusion. Weekly administration also represents the clinical application of the dose-density theory [33] , with the more frequent dosing made possible by the concurrent use of hematopoietic growth factors such as G-CSF. The use of G-CSF is important not only to avert severe hematological toxicity but to maintain the frequency of weekly administration. We should point out that a delay of one unit of time/month means a dose-intensity reduction of 25%. It is well known that dose-intensity reduction impairs breast cancer patient survival in an adjuvant treatment setting [34] , and it is likely that a similar reduction of efficacy will result when treating advanced disease.
The dose-density concept, representing the evolution of treatment intensification according to the NortonSimon hypothesis [35] , has been tested in breast cancer patients receiving chemotherapy in the adjuvant [36] and advanced [37] setting. The weekly administration of the epirubicin-vinorelbine regimen unifies the classical concept of multidrug combination chemotherapy with the concept of dose density. The constant use of G-CSF makes it possible to respect the weekly schedule and contributes to the clinical irrelevance of neutropenia. Moreover, we cannot rule out that the concomitant use of corticosteroids may have contributed to the low clinical relevance of neutropenia.
According to the Gompertzian model of tumor growth, smaller tumors grow faster, so tumor regrowth between treatment cycles is more rapid when cell kill is greatest (adjuvant setting). Reducing the time available for tumor regrowth (increasing dose density), which is now possible through the use of colony-stimulating factors to hasten hematopoietic recovery, may have a greater impact on clinical outcome than dose escalation. The hypothesis and the absence of clinically relevant neutropenia justifies the translation of this high-dosedensity regimen in the adjuvant setting [25] .
In conclusion, our treatment schedule afforded a 77% objective response rate and was remarkably well tolerated. We plan to test the same schedule as an adjuvant regimen in high-risk breast cancer patients with more than four positive lymph nodes and in the neoadjuvant setting.
